InvestorsHub Logo
Followers 9
Posts 2581
Boards Moderated 0
Alias Born 04/15/2012

Re: None

Monday, 08/18/2014 8:36:35 PM

Monday, August 18, 2014 8:36:35 PM

Post# of 15274
About busted a gut laughing at the latest from numbskull Zack's "analyst," Brian Marckx:

"Calmare therapy, which was discovered in the 1980's by Giuseppe Marineo, PhD, an Italian scientist and mathematician, uses low dose electric impulses delivered through electrodes applied to the skin to send a "no pain" message to the brain."

So now, "noodles for brains" Marineo (aka "never even went to college much less obtained an advanced degree") has become a "mathematician" as well???? What a hoot!

One thing he got right:

"Relative to the private healthcare market, we think it's clear that Mir has (wisely) decided that the company's approach in the past of trying to sell to this channel without available meaningful reimbursement was a strategy that had little chance of success."

But what's this nonsense:

"CTI is now re-grouping and dedicating efforts and financial resources towards two pivotal studies that they expect to use to support an FDA PMA filing."

Uhhhhh..."two pivotal studies"??? WHAT studies? I ain't heard nutnin' about no new studies, pivotal or otherwise! Considering the companies flat broke and on life support courtesy of shyster PIPE dealers, I kinda doubt any "pivotal studies" are in CTTC's future!

Not to mention that if CTTC actually filed a for a PMA on a TENS device, the FDA would probably laugh them out of the building!

Hey! There's an idea! Since conclusive "pivotal studies" would no doubt enhance reimbursement as well as patient flow to providers, why not ask THEM to pay for the new studies? Of course, given the way most of their offices look, they probably can barely afford to pay for the electricity a calmare uses, much less dole out money for a study.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.